Site notifications

Sub menu

 

 

Australian prescription medicine decision summaries

Search our decision summaries for the registration of new prescription medicines.

For more information, visit the About Australian prescription medicine decision summaries information page.

We have redesigned our prescription medicine decision summaries (AusPMDSs) to make it easier to understand how prescription medicines are registered in Australia. 

The redesigned AusPMDSs will offer clear, accessible information about recent medicine registration decisions.

Use the filters below to narrow your search.

Filter results

You can narrow down the results using the filters.

Published date

226 result(s) found, displaying 151 to 175

  • Vyepti

    Prescription medicine decision summary
    Australian prescription medicine decision summary

  • Evrysdi

    Prescription medicine decision summary
    Australian prescription medicine decision summary

  • Austedo

    Prescription medicine decision summary
    Australian prescription medicine decision summary

  • Zebinix

    Prescription medicine decision summary
    Australian prescription medicine decision summary

  • Flublok Quadrivalent

    Prescription medicine decision summary
    Australian prescription medicine decision summary

  • Hulio

    Prescription medicine decision summary
    Australian prescription medicine decision summary

  • Cutaquig

    Prescription medicine decision summary
    Australian prescription medicine decision summary

  • Yondelis

    Prescription medicine decision summary
    Australian prescription medicine decision summary

  • Adakveo

    Prescription medicine decision summary
    Australian prescription medicine decision summary

  • Trikafta

    Prescription medicine decision summary
    Australian prescription medicine decision summary

  • Ovaleap

    Prescription medicine decision summary
    TGA decision: Ovaleap (follitropin alfa) is approved to treat anovulatory infertility in woman who are unresponsive to clomiphene citrate.

  • Spravato

    Prescription medicine decision summary
    TGA decision: Spravato (esketamine hydrochloride) is approved for the treatment of treatment resistant depression.

  • Ruxience

    Prescription medicine decision summary
    TGA decision: Ruxience (rituximab) is approved to treat non-Hodgkin's lymphoma, chronic lymphocytic leukaemia, rheumatoid arthritis, GPA and MPA.

  • Zolgensma

    Prescription medicine decision summary
    TGA decision: Zolgensma (onasemnogene abeparvovec) is approved to treat patients less than 9 months old with symptomatic/pre-symptomatic SMA.

  • Abrilada

    Prescription medicine decision summary
    Australian prescription medicine decision summary

  • Vocabria

    Prescription medicine decision summary
    Australian prescription medicine decision summary

  • Poteligeo

    Prescription medicine decision summary
    Australian prescription medicine decision summary

  • Aklief

    Prescription medicine decision summary
    Australian prescription medicine decision summary

  • COMIRNATY

    Prescription medicine decision summary
    Australian prescription medicine decision summary

  • Trientine Waymade

    Prescription medicine decision summary
    TGA decision: Trientine Waymade (trientine dihydrochloride) is approved to treat Wilson's disease patients intolerant to penicillamine.

  • Terrosa

    Prescription medicine decision summary
    TGA decision: TERROSA (teriparatide) is approved to treat osteoporosis in postmenopausal women and primary osteoporosis in men.

  • Enspryng

    Prescription medicine decision summary
    TGA decision: ENSPRYNG (satralizumab) is approved to treat adults with neuromyelitis optica spectrum disorders who have an AQP4-IgG.

  • Reagila

    Prescription medicine decision summary
    TGA decision: Reagila (cariprazine hydrochloride) is approved to treat schizophrenia in adult patients.